INTUITUS
12.10.2016 09:09:49 CEST | Business Wire | Press release
The MD of one of Europe’s leading private equity advisers has warned that technology and IT ‘red flags’ could put at risk the exits or re-financings of companies that would otherwise be seeing deals get over the line successfully with international and London-based institutions and corporate investors.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20161012005052/en/
While various reports have indicated a surge of interest from foreign investors in UK private-equity-owned assets during the second half of 2016 - partly driven by a sharp drop in the value of the pound - that shows signs of continuing into 2017, forward planning in the twelve months leading up to the exit can have a huge impact not only on deal value but whether the deal concludes.
Fixing technology and IT operations can require considerable time and effort, warns Intuitus MD and founder, Calum Stewart:
“Technology has never been more critical to exit readiness than it is today and our client base consistently tells us that if IT problems are discovered in the lead-up to exit it is often too late to redress the situation before potential buyers start taking a look. Potential issues and deal-breakers include intellectual property disputes, contractual disputes, capacity planning and product development problems.”
“In a typical sale process, any significant technology or IT problem presenting a current or future risk will be likely to delay the process and may also depreciate the value that you’re trying to extract. In the worst instance, it could even derail the sale completely.”
- Intuitus - whose private equity clients include Inflexion, The Carlyle Group, Dunedin, Triton and Scottish Equity Partners - is in on track to advise on over 100 deals during 2016, with approximately 30% of deal activity involving non-UK assets.
- Intuitus offers its private equity and corporate clients commercially-focused, independent technology and IT expertise throughout the full investment life cycle - at the point of acquisition, during ownership and at exit. Supported by a network of internationally-experienced consultants, mainly former CEOs, CTOs, CIOs and IT Directors from a wide range of industry sectors, and managed through the company’s unique, integrated delivery model, the company is targeting expansion in the UK, Benelux, France, Germany and the Nordics in 2017.
- Intuitus won the Specialist Adviser of the Year award at The Private Equity Awards 2016.
Follow Intuitus on LinkedIn and Twitter
View source version on businesswire.com: http://www.businesswire.com/news/home/20161012005052/en/
Contact:
Intuitus
Calum Stewart
+44 (0)131 618 0512
or
Freer
Consultancy
Nick Freer
+44 (0)7841 571 871
nick@freerconsultancy.com
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Qualcomm Announces Quarterly Cash Dividend17.4.2026 15:00:00 CEST | Press release
Qualcomm Incorporated (NASDAQ: QCOM) today announced a quarterly cash dividend of $0.92 per common share, payable on June 25, 2026, to stockholders of record at the close of business on June 4, 2026. About Qualcomm Qualcomm relentlessly innovates to deliver intelligent computing everywhere, helping the world tackle some of its most important challenges. Building on our 40 years of technology leadership in creating era-defining breakthroughs, we deliver a broad portfolio of solutions built with our leading-edge AI, high-performance, low-power computing, and unrivaled connectivity. Our Snapdragon® platforms power extraordinary consumer experiences, and our Qualcomm Dragonwing™ products empower businesses and industries to scale to new heights. Together with our ecosystem partners, we enable next-generation digital transformation to enrich lives, improve businesses, and advance societies. At Qualcomm, we are engineering human progress. Qualcomm Incorporated includes our licensing business
Byondis to Present Data from its Novel ADC Technology Platforms at the American Society for Cancer Research Meeting 202617.4.2026 13:00:00 CEST | Press release
Byondis B.V., an independent biopharmaceutical company creating innovative targeted medicines for patients with cancer, will profile the Company’s first-in-class antifolate and phosphonate antibody-drug conjugate (ADC) technology platforms in poster sessions at the American Society for Cancer Research (AACR) Annual Meeting 2026 in San Diego, CA, from today through to 22 April. Wim Dokter, PhD, Chief Scientific Officer at Byondis, said: “The research we are presenting at AACR highlights the potential of two of our state-of-the-art ADC technology platforms to address significant limitations with current therapeutic approaches in cancer treatment. Our first-in-class antifolate linker-drug platform features an orthogonal mechanism of action based on clinically validated biology. This approach is engineered to address acquired resistance that can develop with current ADC treatments, positioning it for use across treatment lines. Our phosphonate linker-drug platform offers a complementary me
BlackBerry, JVCKENWOOD and SK Telecom Join Sisvel POS Patent Pool as Licensors17.4.2026 09:04:00 CEST | Press release
The new Sisvel Point of Sale (POS) patent pool, announced on 1 April, has added three new licensors in the last two weeks. BlackBerry, JVCKENWOOD and SK Telecom have joined founding licensors Huawei, LG Electronics and Nokia in making their patents available for license through the programme. Sisvel POS covers 2G, 3G, 4G and 5G technologies. It is the first joint licensing programme to address point of sale devices – a category of product that has leveraged cellular connectivity to transform customer payment processing. Participating patent owners make their relevant standards essential patents (SEPs) available on FRAND terms, simplifying access to essential IP rights for POS device makers. Early participation incentives for licensors are available until mid-May. Parties interested in joining the pool are encouraged to contact Sisvel as soon as possible. “BlackBerry, JVCKENWOOD and SK Telecom are first-rate cellular innovators. I am pleased they have chosen to become part of Sisvel POS
Adtran wins two FTTH Innovation Awards for AI‑driven network operations and home Wi‑Fi17.4.2026 09:00:00 CEST | Press release
News summary: Mosaic One Clarity recognized for applying explainable AI to shift fiber operations from reactive troubleshooting to proactive assurance Adtran’s SDG 8000 and 9000 Series honored for delivering multigigabit, whole‑property Wi‑Fi with unified software and cloud management Awards highlight Adtran’s focus on innovation that helps service providers scale fiber efficiently while improving customer experience Adtran today announced two wins at the FTTH Innovation Awards 2026, recognizing its leadership across in-home connectivity and AI‑driven network operations. The company received awards in the categories for ‘Active infrastructure – home network’ and ‘Artificial intelligence (AI), machine learning and other software.’ Organized by FTTH Council Europe, the annual awards honor technologies that advance fiber deployment while improving scalability, operational efficiency and user experience. Voted by FTTH Conference 2026 speakers, the results reflect peer recognition for Mosai
Samsung Bioepis Highlights Consistent Efficacy of SB16 (OBODENCE®; Denosumab) Across Osteoporosis Patient Subgroups at WCO-IOF-ESCEO 202617.4.2026 08:00:00 CEST | Press release
- Subgroup analysis from Phase 3 study demonstrates consistent efficacy of SB16 across key patient populations - Results reinforce the totality-of-evidence supporting SB16 biosimilarity Samsung Bioepis Co., Ltd. announced today new data supporting consistent efficacy of SB16 (OBODENCE®1), a biosimilar to Prolia2 (denosumab) across patient subgroups compared to the reference denosumab. The data will be presented as a poster presentation at the World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (WCO-IOF-ESCEO) 2026 in Prague from April 16 to 19. “Consistent efficacy across patient subgroups is critical in reinforcing physician confidence and advancing treatment accessibility for patients with osteoporosis,” said Jeehoon Ghil, Vice President and Medical & Lifecycle Safety Team Leader at Samsung Bioepis. “Such data contribute to the robustness of the overall biosimilarity assessment and support the clinical confidence in our denosumab biosimilar.” SB16 was evaluate
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
